Fitt Insider Equinox's Longevity Membership, Meta's Smartwatch, Grail's Cancer Screening
Feb 24, 2026
A quick rundown of a major tech player reentering the smartwatch market with AI health tracking and tie-ins to smart glasses. A high-profile blood screening test misses its primary goal in a large UK trial, triggering market turbulence. A luxury $40,000-per-year fitness and longevity membership draws a long waitlist with biomarker testing and concierge services.
AI Snips
Chapters
Transcript
Episode notes
Meta Returns To Smartwatches With AI Health Focus
- Meta is re-entering the smartwatch market with a device codenamed Malibu 2 that combines health tracking and AI features.
- The watch may integrate with Ray-Ban smart glasses and signals Big Tech's push to tie AI-powered hardware into health ecosystems.
Grail Trial Undercuts Multi Cancer Screening Hopes
- GRAIL's $949 Galleri multi-cancer blood test failed to show a statistically significant reduction in late-stage cancer diagnoses in a major UK trial.
- Executives pointed to secondary shifts from stage 4 to stage 3, but the trial missing its primary endpoint casts doubt on the multi-cancer early detection category.
Equinox Hits 1,000+ Waitlist For $40K Longevity Club
- Equinox's $40,000 per year Optimize membership has amassed a waitlist of over 1,000 people, showing demand for luxury longevity services.
- The program bundles biomarker testing, personal training, sleep coaching, IV therapy, and a dedicated health concierge.